RaySearch and Mevion Medical Systems, two leaders in the field of technology for proton therapy, are extending their collaboration agreement to support the RayCare® oncology information system (OIS), which is currently in development at RaySearch, and to take full advantage of the advanced treatment capabilities of the MEVION S250i with HYPERSCAN with Adaptive Aperture. The agreement was announced at the 58th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160926005886/en/
The MEVION S250i with HYPERSCAN with Adaptive Aperture is the gold standard of pencil beam scanning. (Photo: Business Wire)
RayCare is the next-generation OIS, developed from the ground up by RaySearch to support the complex logistical challenges in modern, large-scale radiation therapy centers. RayCare integrates the high-performance radiation therapy algorithms available in RayStation® and adds advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. The system is expected to be released in 2017.
Adaptive Aperture is a proprietary low-profile micro-multileaf collimator system designed specifically for HYPERSCAN pencil beam scanning. Its unique layer-by-layer beam collimation and blocking achieves unprecedented one to three millimeter collimated spot sizes, for all energies, at any depth. Under the agreement, RaySearch will develop planning capabilities to support the layer-by-layer collimation of Adaptive Aperture.
Previous collaboration between RaySearch and Mevion has led to impressive results at Mevion customer sites, such as Ackerman Cancer Center (ACC) in Jacksonville, Florida. ACC commissioned RayStation for its MEVION S250 in just two weeks, achieving the fastest clinical ramp-up in proton therapy history. The center is now treating more than 40 patients per day in a single proton therapy room.
Townsend Zwart, Senior Director of Advanced Development at Mevion Medical Systems, says, “Adaptive Aperture is ideal for intensity modulated proton therapy (IMPT) because it creates the sharpest penumbra physically achievable without the need for manual apertures and adjustments. We are excited to extend our relationship with RaySearch to help radiation oncologists make the most of this advanced technology.”
Johan Löf, CEO of RaySearch, says, “Partnering with Mevion, the market leader in compact proton therapy systems, enables us to provide cancer centers with a complete turnkey solution to deliver the world’s most advanced proton therapy treatment.”
More information about the collaboration between RaySearch and Mevion is available at the RaySearch booth (#12012) and the Mevion booth (#10031) in the ASTRO exhibit hall.
About Mevion Medical Systems®
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in the Europe, Japan and China. For more information, please visit www.mevion.com.
About the MEVION S250 Series™
The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefitting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is a high-quality treatment with reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers. The MEVION S250 Series includes:
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and which will be launched in 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on NASDAQ Stockholm since November 2003. More information about RaySearch is available at www.raysearchlabs.com.
RayCare and the MEVION S250i Proton Therapy System with HYPERSCAN with Adaptive Aperture are not yet FDA cleared.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160926005886/en/Business Wire
Last updated on: 26/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.